 | This article needs to be updated. (December 2016) |
| Company type | Public |
|---|---|
| Founded | 1980 |
| Headquarters | Cambridge, Massachusetts, U.S. |
Key people | Douglas S. Ingram (CEO & president) |
| Revenue |  US$1.145 billion (2023)[1] |
Number of employees | 1,314 (December 2023) |
| Website | sarepta |
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals,[2] shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively.[3] As of 2023, the company has four approved drugs (see the Products section below).
- ^ "FORM 10-K". UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Retrieved 2024-10-28.
- ^ Summerton, J (2005). "Morpholino Antisense Oligos: Applications in Biopharmaceutical Research". Innovations in Pharmaceutical Technology. No. Sept. Retrieved 29 Oct 2012. | archiveurl = http://www.gene-tools.com/sites/default/files/Summerton2005_IPT.pdf
- ^ "AVI BioPharma changes name, splits stock". Portland Business Journal. July 12, 2012. Retrieved 17 July 2012.